Cumberland Pharmaceuticals
CPIX
36 hedge funds and large institutions have $38.2M invested in Cumberland Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 4 closing their positions.
100% more capital inflows, than outflows
Capital inflows: $5.42M | Capital outflows: $2.72M
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
0.51% more ownership
Funds ownership: 33.88% → 34.39% (+0.51%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
12% less funds holding
Funds holding: 41 → 36 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.54M |
| 2 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$1.53M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$730K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$144K |
| 5 |
Bridgeway Capital Management
Houston,
Texas
|
+$99.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ariel Investments
Chicago,
Illinois
|
-$2.62M |
| 2 |
BA
Bard Associates
Chicago,
Illinois
|
-$23.9K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$21.8K |
| 4 |
Ancora Advisors
Cleveland,
Ohio
|
-$20K |
| 5 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$12.1K |
CPIX Hedge Fund Activity: Q1 2017 in Review
36 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q1 2017, worth a combined $38.2M — up 27% from $30.2M a quarter earlier.
Fund positioning in CPIX was balanced in Q1 2017: 4 funds opened new positions, 4 closed out, 10 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $2.54M. The largest seller was Ariel Investments, cutting an estimated $2.62M.
- 36 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q1 2017, down from 41 in Q4 2016.
- Funds reported $38.2M of Cumberland Pharmaceuticals stock for Q1 2017, up 27% quarter-over-quarter.
- 4 funds opened new Cumberland Pharmaceuticals positions in Q1 2017 and 4 closed out, a net change of 0 holders.
- The largest Cumberland Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $2.54M added.
- The largest Cumberland Pharmaceuticals seller in Q1 2017 was Ariel Investments, an estimated $2.62M sold.
Based on aggregated 13F filings for Q1 2017.